Skip to content

Erasca, Inc. ERAS Short- term Investments

Short- term Investments at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Tango Therapeutics logo
Tango TherapeuticsTNGX
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
Exelixis logo
ExelixisEXEL
Corcept Therapeutics logo
Corcept TherapeuticsCORT

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s short- term investments?
Erasca, Inc. (ERAS) reported short- term investments of $196.53M in Q1 2026.
How has Erasca, Inc.'s short- term investments changed year-over-year?
Erasca, Inc.'s short- term investments decreased by 16.0% year-over-year, from $234.1M to $196.53M.
What is the long-term trend for Erasca, Inc.'s short- term investments?
Over 4 years (2021 to 2025), Erasca, Inc.'s short- term investments has grown at a 39.1% compound annual growth rate (CAGR), from $53.99M to $202.27M.